OREANDA-NEWS The British-Swedish pharmaceutical company AstraZeneca has challenged the patent for the Russian equivalent of its cancer drug Tagrisso. RBC writes about this with reference to Rospatent data.

We are talking about the domestic drug "Osimertinib" from the manufacturer "Axelpharm". The agency made the relevant decision on August 14, and AstraZeneca's objection to the patent was sent back in September last year.

Used in the treatment of lung cancer, Tagrisso was registered in the Russian Federation in 2017, the patent for the drug is valid until 2032. AstraZeneca assured that the drug is produced at the plant in the Kaluga region in volumes that "fully meet the needs of Russian patients," and there has been no shortage of it.